Beyond Dopamine: Glutamate as a Target for Future Antipsychotics

Kyra-Verena Sendt,1 Giovanni Giaroli,2,3 and Derek K. Tracy3,4

1 Department of Psychosis Studies, Institute of Psychiatry, King’s College London, London SE5 8AF, UK
2 North East London NHS Foundation Trust, Ilford IG3 8XJ, UK
3 Cognition, Schizophrenia and Imaging Laboratory, Department of Psychological Medicine, Institute of Psychiatry, King’s College London, London SE5 8AF, UK
4 Oxleas NHS Foundation Trust, Princess Royal University Hospital, Orpington BR6 8NY, UK

Correspondence should be addressed to Kyra-Verena Sendt, kyra-verena.sendt@kcl.ac.uk

Received 29 April 2012; Accepted 6 June 2012

The dopamine hypothesis of schizophrenia remains the primary theoretical framework for the pharmacological treatment of the disorder. Despite various lines of evidence of dopaminergic abnormalities and reasonable efficacy of current antipsychotic medication, a significant proportion of patients show suboptimal treatment responses, poor tolerability, and a subsequent lack of treatment concordance. In recent decades, intriguing evidence for the critical involvement of other neurotransmitter systems in the pathophysiology of schizophrenia has emerged, most notably of dysfunctions within the glutamate pathways. Consequently, the glutamate synapse has arisen as a promising target for urgently needed novel antipsychotic compounds—particularly in regards to debilitating negative and cognitive symptoms poorly controlled by currently available drugs. In this paper, recent findings integrating glutamatergic and dopaminergic abnormalities in schizophrenia and their implications for novel pharmacological targets are discussed. An overview of compounds in various stages of development is given: drugs enhancing NMDA receptor function as well as metabotropic glutamate receptor (mGluR) agonist and positive allosteric modulators (PAMs) are emphasised. Together with other agents more indirectly affecting glutamatergic neurotransmission, their potential future role in the pharmacotherapy of schizophrenia is critically evaluated.

1. Introduction

Since the development of chlorpromazine in the 1950s antipsychotic drugs have been the primary treatment choice for schizophrenia [1]. The common pharmacological antagonism of dopamine (DA) D2 receptors by all antipsychotics and direct link with clinical improvement led to the theory of excess dopaminergic neurotransmission precipitating psychotic states [2–4]. Later, advances in animal, postmortem, and neuroimaging studies led to refinements of the dopamine hypothesis and a regional specificity of abnormal DA signalling was proposed. Negative symptoms of schizophrenia (such as anhedonia, flat or blunted affect, alogia, and avolition) as well as cognitive impairments (including deficits in executive functions, attention, and working memory) were postulated to be caused by deficiencies in DA transmission at D1 receptors in mesocortical projections to the prefrontal cortex (PFC). This dysregulation in cortical DA pathways, through a reciprocal relationship with subcortical DA projections, was hypothesised to cause a hyperdopaminergic state at D2 receptors in mesolimbic DA projections, resulting in positive symptoms of the disorder (such as hallucinations and delusions) [5–8]. Psychotomimetic effects of indirect DA agonists, such as amphetamines, in healthy individuals [9, 10] as well as more recent neuroimaging findings-linking increased DA synthesis at presynaptic striatal D2 receptors to positive symptoms [11, 12] and DA deficiencies in PFC areas to cognitive deficits [13–15] have lent further support to the dopamine hypothesis. In addition, associations between specific candidate genes and dopaminergic dysfunction in schizophrenia have been identified [16–18].
Whilst first-generation antipsychotics (FGAs) are characterised by their principal blockade of D₂ receptors, second-generation “atypical” compounds comprise a more heterogeneous pharmacological profile involving actions on multiple neurotransmitter systems [19, 20]. Despite widespread anticipation of better tolerability of these newer agents (particularly in regards to extrapyramidal side effects associated with FGAs), metabolic complications such as weight gain, impaired glucose tolerance, and dyslipidaemia are commonly occurring side effects [21]. Further, it is estimated that one third of patients do not respond adequately to antipsychotic medication [22–24], with only clozapine showing better efficacy than FGAs in treatment-resistant schizophrenia [25, 26]. While positive symptoms are generally reasonably well controlled by antipsychotic treatment, negative and cognitive symptom clusters commonly fail to respond in a large proportion of patients [27–29], though their severity is associated with longer-term clinical outcomes [30–32].

These factors underline the urgent need for novel compounds with improved tolerability and efficacy, particularly for negative and cognitive symptoms. Research has identified other neurotransmitter systems in addition to dopamine in the pathology of schizophrenia [33–35]. Most prominently, work on the role of glutamate—the primary excitatory neurotransmitter in the central nervous system—forms the basis of efforts into developing the first nondopaminergic compounds in sixty years of pharmacotherapeutic treatment of schizophrenia [36–42].

**2. Glutamate and Schizophrenia**

### 2.1. The Glutamate Hypothesis of Schizophrenia

Two main types of receptors underlie glutamatergic neurotransmission: the ligand-gated ionotropic receptor family, divided into α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA) and kainate receptors, and the G-protein coupled metabotropic receptor (mGluR) family comprising groups I to III with a total of eight identified subtypes [43]. While ionotropic receptors, in particular AMPA and NMDA, mediate fast excitatory transmission at the glutamate synapse, ligand binding at metabotropic receptors leads to conformational changes directly or indirectly affecting neurotransmission via second messenger pathways [44]. A number of shortcomings of the historically prevailing dopamine hypothesis—most prominently the suboptimal or lacking clinical response of negative and cognitive symptoms to D₂ antagonism and findings of structural brain changes associated with the schizophrenia—inspired the integration of glutamate into a theoretical framework of the disorder [45–47]. The observation that administration of noncompetitive NMDA receptor (NMDAR) antagonists like phencyclidine (PCP) and ketamine could mimic symptoms of schizophrenia in healthy individuals gave rise to the hypothesis of impaired NMDAR functioning contributing to its pathophysiology [48–50]. Importantly, it was found that PCP and ketamine immediately and reliably induced symptom patterns identical to the cognitive impairments and negative symptoms of schizophrenia not observed under amphetamine challenge [51]. In recent years, several lines of evidence have suggested that reduced glutamatergic excitation of subcortical gamma-amino-butyric acid (GABA) interneurons, through an initial hypofunction of NMDAR, results in disinhibition of glutamate (as well as dopamine and acetylcholine) neurotransmission to the cortex [49, 52–54]. In addition, increased glutamate signalling mainly at AMPA receptors has been found to be a possible downstream effect of NMDAR blockade [38, 55]. Hence, refinements of the glutamate hypothesis postulate that behavioural and cognitive symptoms of schizophrenia appear to be caused by a dysregulation of glutamatergic neurotransmission, characterised by NMDAR hypofunction and subsequent excess glutamatergic activity.

### 2.2. Evidence for the Glutamate Hypothesis of Schizophrenia

Evidence for glutamatergic abnormalities in schizophrenia comprises findings from a range of animal models and human methodologies. In rodents, higher cortical glutamate levels after NMDAR antagonist injections into thalamic structures have been linked to cortical neurotoxic changes reminiscent of grey matter volume reductions in patients with schizophrenia [49, 56, 57]. In addition, persistent, long-term cognitive impairments similar to cognitive dysfunction in schizophrenia have been observed in rodents as a result of NMDAR antagonist-induced neurotoxicity in prefrontal cortical areas [58]. Despite lacking evidence for abnormal cerebrospinal fluid glutamate levels in patients with schizophrenia [48, 59], recent advances in neuroimaging have given rise to more consistent support for glutamatergic abnormalities. Pilowsky et al. [60] employed single photon emission tomography (SPET) in unmedicated patients with schizophrenia and demonstrated a reduction in NMDA receptor binding compared to healthy controls in hippocampal areas. A number of proton magnetic resonance spectroscopy (¹H-MRS) studies have found increased levels of prefrontal glutamatergic neurotransmission in unmedicated patients during early disease stages, which appeared to be normalised in chronic patients [41, 61–63], reflecting a possible influence of antipsychotic treatment and/or disease progression on glutamate signalling. Structural abnormalities of NMDA receptors in schizophrenia [40] as well as reduced levels of the endogenous neurotransmitter D-serine have further been documented [64, 65]. As either glycine or D-serine is required as a coagonist with glutamate for channel opening at the NMDAR glycine site, D-serine levels appear to reflect glutamatergic neurotransmission [66]. Finally, a number of possible candidate risk genes for schizophrenia involved in glutamate signalling have been proposed, including polymorphisms of several NMDAR subunits and allelic variations of mGlu receptors [67–70].

### 2.3. Integration with the Dopamine Hypothesis

Several unifying approaches have been made in recent years to integrate the evidence for glutamatergic abnormalities and dopamine in the pathogenesis and current treatment of schizophrenia [34, 42, 71, 72]. A current, widely supported theory states that dopaminergic imbalances in striatal and cortical areas
are preceded and modulated by NMDAR hypofunction in the PFC. In turn, the arising dopaminergic dysregulation might further disrupt glutamatergic signalling at NMDA receptors [39, 73, 74]. Dopaminergic dysregulation might thus be the result of primary impairments of glutamate neurotransmission and a subsequent reinforcing factor in maintaining these impairments [75]. In fact, lower glutamate levels in hippocampal areas of individuals in the prodromal states of schizophrenia, but not in healthy controls, have been found to be linked to increased dopaminergic neurotransmission [76].

3. Glutamatergic Drugs for Schizophrenia

3.1. Currently Available Compounds. No drug targeting glutamate neurotransmission has yet been licensed for schizophrenia. Several compounds approved for other indications, however, have been identified as additionally affecting glutamate neurotransmission. Lamotrigine, an anticonvulsant, inhibits glutamate release by acting on presynaptic sodium channels [77] and has been experimentally used as an adjunct treatment in schizophrenia. Although a Cochrane review concluded with a lack of robust evidence for its efficacy [78], a more recent meta-analysis suggests moderate effects for use in patients with suboptimal response to clozapine [79]. Another anticonvulsant, topiramate, exhibits antagonistic actions at AMPA and kainate receptors [80] and has been used to augment standard antipsychotic treatment [81], though its efficacy is modest [82, 83]. There is similarly some evidence for the tetracycline antibiotic minocycline, which exhibits neuroprotective actions by depressing glutamate-induced excitotoxicity [84–87]. Nevertheless, current data is underwhelming, and further large-scale randomised controlled trials into all these agents are required.

3.2. NMDAR Enhancing Agents. The development of novel drugs with antipsychotic properties through direct binding on the glutamate site of the NMDA receptor has proven challenging. Its wide distribution in the central nervous system—associated with decreased tolerability—and the potentially neurotoxic effects of receptor overactivation have stimulated the search for compounds more indirectly affecting glutamatergic signalling [36, 88]. Attempts to develop NMDA receptor enhancing treatments have most notably focused on full agonists of the glycine modulatory site of the NMDAR—glycine and D-serine—as well as sarcosine, a glycine transporter type 1 (GlyT1) inhibitor.

Discouragingly, the Cognitive and Negative Symptoms in Schizophrenia trial (CONSIST) found no beneficial effect of using glycine as an add-on treatment in chronic schizophrenia [89]. A recent meta-analysis by Tsai and Lin [90] found a consistently good tolerability of both glycine and D-serine as adjunct treatments but failed to demonstrate more convincing evidence for their efficacy than moderate effect sizes for negative symptoms and small effect sizes for positive and cognitive symptoms. Interestingly, no additional benefits could be observed for patients receiving clozapine treatment, possibly due to clozapine’s action as a partial NMDAR agonist and the generally later disease stage in this group of patients [91, 92]. Whilst evidence to date for adjunctive D-serine has been weak, there is some data to indicate this might be due to inadequate dosing [93]. Trials of indirectly increasing D-serine by inhibiting the metabolising enzyme D-amino acid oxidase (DAAO) have not yet advanced to clinical phases [94, 95].

An alternative approach to enhancing glycine levels is the inhibition of glycine reuptake via type 1 glycine transporters (GlyT1). Sarcosine, the endogenous GlyT1 inhibitor, has demonstrated efficacy in alleviating positive, negative, and general symptoms of schizophrenia as an adjunct treatment to nonclozapine antipsychotics [96], both in the acute phase [97] and in chronically ill patients [98, 99]. Lane et al. [100] investigated sarcosine as monotherapy for schizophrenia and found some efficacy, with 2 g/day producing stronger symptom reduction than 1 g/day, but lacked placebo as well as active control groups. While no published results are available for the selective GlyT1 inhibitor ORG25935 developed by Merck (phase II completed), Roche’s compound RG1678/RO4917838 has entered phase III testing after moderately beneficial results in reducing positive and negative symptoms as an adjunct treatment were reported [101, 102].

3.3. Metabotropic Glutamate Receptor Compounds. A multitude of potential new antipsychotic drugs target the less widely distributed metabotropic glutamate receptors (mGluRs) as agonists or positive allosteric modulators (PAMs). Selective agonists at mGlu2/3 receptors are thought to exert their antipsychotic actions by limiting glutamate release presynaptically and have been shown to attenuate the effects of NMDAR antagonists in humans [38, 103]. Animal models have suggested reduced PCP-induced dopamine signalling in striatal areas and increased dopaminergic neurotransmission in the PFC after administration of mGlu2/3 agonists [56, 104, 105]. As a result, compounds of this type have been predicted to alleviate negative, cognitive, and positive symptoms [106]. Monotherapy with pomaglumetad methionil (LY2140023, an oral prodrug of LY404039) developed by Eli Lilly demonstrated superior efficacy to placebo and equal results to olanzapine in reducing positive and negative symptoms of schizophrenia in a phase II trial while being well-tolerated [107]. These findings could not be replicated in a follow-up trial as neither pomaglumetad nor olanzapine showed greater efficacy than placebo while the incidence of a number of adverse events limited the drug’s tolerability. Nevertheless, the compound has recently entered phase III for long-term testing and head-to-head comparisons with atypical antipsychotics (https://www.clinicaltrials.gov/). In contrast to mGlu2/3 agonists, selective agonists at mGlu5 receptors—which are located mainly postsynaptically and are thought to modulate NMDAR function by increasing NMDAR-mediated current—have not yet reached clinical stages [106].

While the potential of alleviating cognitive symptoms in schizophrenia via mGlu5R agonism has stimulated interest in this target [108], full agonistic action at orthosteric
sites of mGluRs (that is, primary sites of endogenous ligand binding) has generally been associated with receptor downregulation and an increased risk of neurotoxic effects [109–111]. Consequently, a number of compounds targeting the allosteric site of mGluRs have been developed, some of which have reached clinical testing phases. As binding to an allosteric site only modulates the receptor in the presence of an endogenous ligand—therefore causing transient and activity-dependent changes—unfavourable effects of orthosteric agonists could potentially be avoided [112, 113]. Several generations of selective positive allosteric modulators at mGlu5 receptors (MGlu5R PAMs) have shown potential in animal models for their antipsychotic properties [114, 115]. Most notably, potential reductions in all symptom areas of schizophrenia have been suggested for the compound ADX-47273 currently in preclinical development by Addex [116, 117] and transition into clinical testing is awaited. Although an mGlu2/3 receptor PAM compound (AZD8529), developed by AstraZeneca, has recently completed a phase II trial, no reports have been published to date and it is unclear if further development of this drug can be expected [88]. Encouraging results from preclinical studies, however, have suggested antipsychotic potential for selective positive allosteric modulators at the mGlu2 receptor. As growing evidence from animal studies has emphasized the critical role of the mGlu2 receptor in mediating the clinical effects of this group of compounds [118, 119], potent selectivity for this subtype might yield increased efficacy. Notably, strong potential for antipsychotic action has been demonstrated for the two major prototypes, LY487379 and Biphenylindanone A (BINA), resembling results of the aforementioned orthosteric mGlu2/3 agonists [120–122].

3.4. Other Potential Targets. In addition to targeting NMDAR and metabotropic glutamate receptors, several research efforts have focused on PAMs for the ionotropic AMPA receptor, so-called “ampakines”. Based on animal models of improved memory, attention and learning through enhanced glutamatergic signalling [123, 124], the AMPA PAM prototype CX516, developed by Shire and Servier and Cortex, showed preliminary evidence in clinical trials for enhancing cognitive function as an adjuvant treatment in schizophrenia [125]. In line with the failure to reproduce these results in a larger trial [126], phase II trials of the related compound Farampator (ORG24448) developed by Cortex were terminated and results have not been published [127]. While it remains unclear whether research into these agents for the treatment of schizophrenia will be continued, a number of non glutamatergic targets indirectly modulating the glutamate system have shown promise. In particular, potential antipsychotic properties have been preliminary demonstrated for the nonhallucinogenic cannabinoid cannabidiol (CBD) [128–130] as well as the selective muscarinic M1/M4 receptor agonist xanomeline in development by Lilly [131, 132]. Further preclinical work is required, however, to evaluate their suitability for use as antipsychotic treatment.

4. Conclusion

Although supported by a large body of evidence and dominating decades of research into aetiology and treatment, the dopamine hypothesis of schizophrenia insufficiently accounts for the complexities of the disorder. Both generations of dopaminergic antipsychotics leave a substantial proportion of patients suboptimally treated, particularly regarding negative and cognitive symptoms, as well as having significant side effects that limit patient concordance with treatment. The clinical and financial costs of psychosis are enormous and the need for novel antipsychotic compounds is acute. Better understanding of the neuropathology of schizophrenia has highlighted the involvement of alternative neurotransmitter systems and, in particular, the potential of the glutamate synapse for providing new pharmacological targets has arisen. Abnormal glutamate neurotransmission has been linked to the prodromal phase of schizophrenia and early psychotic episodes and with the frequently treatment refractory processes of negative and cognitive symptoms. Consequently, compounds aiming at restoring glutamatergic dysregulation could provide relief for symptoms not optimally treated by current antipsychotic drugs, intervene in a potentially critical disease stage and have downstream effects on dopaminergic neurotransmission. A variety of glutamatergic agents in development are currently undergoing preclinical and clinical testing. A number of compounds licensed for medical conditions, several NMDAR enhancing drugs as well as different mGlu agonists and PAMs have accumulated preclinical and, in part, early clinical evidence for use in antipsychotic treatment. Most notably, a GlyT1 inhibitor and an agent modulating glutamate signalling through selective agonistic action at mGlu2/3 receptors have shown promising antipsychotic efficacy as well as favourable side effect profiles and have recently been entered into phase III trials. While these encouraging advances, together with the emergence of new potential agents, instil confidence in a timely identification of novel antipsychotic drugs, moderate or inconclusive results of several compounds emphasise the need for further large-scale, high-quality research efforts. In particular, efficacy of promising candidate drugs, their role in antipsychotic monotherapy or adjunct treatment as well as their long-term safety and tolerability require confirmation and clarification.

References

[1] S. Kapur and D. Mamo, “Half a century of antipsychotics and still a central role for dopamine D2 receptors,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 7, pp. 1081–1090, 2003.
[2] I. Creese, D. R. Burt, and S. H. Snyder, “Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs,” Science, vol. 192, no. 4238, pp. 481–483, 1976.
[3] P. Seeman, M. Chau Wong, J. Tedesco, and K. Wong, “Brain receptors for antipsychotic drugs and dopamine: direct binding assays,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 11, pp. 4376–4380, 1975.
[4] P. Seeman, T. Lee, M. Chau Wong, and K. Wong, “Antipsychotic drug doses and neuroleptic/dopamine receptors,” *Nature*, vol. 261, no. 5562, pp. 717–719, 1976.

[5] K. L. Davis, R. S. Kahn, G. Ko, and M. Davidson, “Dopamine in schizophrenia: a review and reconceptualization,” *American Journal of Psychiatry*, vol. 148, no. 11, pp. 1474–1486, 1991.

[6] Y. Okubo, T. Suhara, K. Suzuki et al., “Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET,” *Nature*, vol. 385, no. 6617, pp. 634–635, 1997.

[7] P. Seeman and H. H. M. Van Tol, “Dopamine receptor pharmacology,” *Trends in Pharmacological Sciences*, vol. 15, no. 7, pp. 264–270, 1994.

[8] D. R. Weinberger, “Implications of normal brain development for the pathogenesis of schizophrenia,” *Archives of General Psychiatry*, vol. 44, no. 7, pp. 660–669, 1987.

[9] R. E. Featherstone, S. Kapur, and P. J. Fletcher, “The amphetamine-induced sensitized state as a model of schizophrenia,” *Progress in Neuro-Pharmacology and Biological Psychiatry*, vol. 31, no. 8, pp. 1556–1571, 2007.

[10] J. A. Lieberman, J. M. Kane, and J. Alvir, “Provocative tests with psychostimulant drugs in schizophrenia,” *Psychopharmacology*, vol. 91, no. 4, pp. 415–433, 1987.

[11] O. D. Howes, E. Egerton, V. Allan, P. McGuire, P. Stokes, and S. Kapur, “Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging,” *Current Pharmaceutical Design*, vol. 15, no. 22, pp. 2550–2559, 2009.

[12] L. S. Kegeles, A. Abi-Dargham, W. G. Frankle et al., “Increased synaptic dopamine function in associative regions of the striatum in schizophrenia,” *Archives of General Psychiatry*, vol. 67, no. 3, pp. 231–239, 2010.

[13] A. Abi-Dargham and H. Moore, “Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia,” *Neuroscientist*, vol. 9, no. 5, pp. 404–416, 2003.

[14] A. Meyer-Lindenberg, R. S. Miletich, P. D. Kohn et al., “Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia,” *Nature Neuroscience*, vol. 5, no. 3, pp. 267–271, 2002.

[15] A. S. Meyer-Lindenberg, R. K. Olsen, P. D. Kohn et al., “Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia,” *Archives of General Psychiatry*, vol. 62, no. 4, pp. 379–386, 2005.

[16] T. E. Goldberg, R. E. Straub, J. H. Callicott et al., “The G72/G30 gene complex and cognitive abnormalities in schizophrenia,” *Neuropsychopharmacology*, vol. 31, no. 9, pp. 2022–2032, 2006.

[17] L. Zhan, J. R. Kerr, M. J. Lafuente et al., “Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder,” *Neuropathology and Applied Neurobiology*, vol. 37, no. 2, pp. 206–219, 2011.

[18] F. Zhu, C.-X. Yan, Q. Wang et al., “An association study between dopamine D1 receptor gene polymorphisms and the risk of schizophrenia,” *Brain Research*, vol. 1420, pp. 106–113, 2011.

[19] X. López-Gil, F. Artigas, and A. Adell, “Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex,” *Current Pharmaceutical Design*, vol. 16, no. 5, pp. 502–515, 2010.

[20] P. S. Talbot and M. Laruelle, “The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development,” *European Neuropsychopharmacology*, vol. 12, no. 6, pp. 503–511, 2002.

[21] G. P. Reynolds and S. L. Kirk, “Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms,” *Pharmacology and Therapeutics*, vol. 125, no. 1, pp. 169–179, 2010.

[22] T. R. Barnes and S. Dursun, “Treatment resistance in schizophrenia,” *Psychiatry*, vol. 4, no. 11, pp. 68–70, 2005.

[23] J. A. Lieberman, T. Scott Stroup, J. P. McEvoy et al., “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia,” *New England Journal of Medicine*, vol. 353, no. 12, pp. 1209–1223, 2005.

[24] T. Suzuki, G. Remington, B. H. Mulsant et al., “Treatment resistant schizophrenia and response to antipsychotics: a review,” *Schizophrenia Research*, vol. 133, no. 1–3, pp. 54–62, 2011.

[25] J. Geddes, N. Freeman, P. Harrison, and P. Bebbington, “Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis,” *British Medical Journal*, vol. 321, no. 7273, pp. 1371–1376, 2000.

[26] S. Leucht, C. Corves, D. Arbter, R. R. Engel, C. Li, and J. M. Davis, “Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis,” *The Lancet*, vol. 373, no. 9657, pp. 31–41, 2009.

[27] R. W. Buchanan, “Persistent negative symptoms in schizophrenia: an overview,” *Schizophrenia Bulletin*, vol. 33, no. 4, pp. 1013–1022, 2007.

[28] G. Foussias and G. Remington, “Negative symptoms in schizophrenia: avolition and occam’s razor,” *Schizophrenia Bulletin*, vol. 36, no. 2, pp. 359–369, 2010.

[29] S. Leucht, K. Wahlbeck, J. Hamann, and W. Kissling, “New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis,” *The Lancet*, vol. 361, no. 9369, pp. 1581–1589, 2003.

[30] A. K. J. Fett, W. Viechtbauer, M. D. G. Dominguez, D. L. Penn, J. van Os, and L. Krabbendam, “The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis,” *Neuroscience and Biobehavioral Reviews*, vol. 35, no. 3, pp. 573–588, 2011.

[31] M. M. Kurtz, P. J. Moberg, J. Daniel Ragland, R. C. Gur, and R. E. Gur, “Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study,” *Schizophrenia Bulletin*, vol. 31, no. 1, pp. 167–174, 2005.

[32] S. Shamisi, A. Lau, T. Lencz et al., “Cognitive and symptomatic predictors of functional disability in schizophrenia,” *Schizophrenia Research*, vol. 126, no. 1–3, pp. 257–264, 2011.

[33] J. Hirvonen and J. Hietala, “Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems,” *CNS Neuroscience and Therapeutics*, vol. 17, no. 2, pp. 89–96, 2011.

[34] J. E. Lisman, J. T. Coyle, R. W. Green et al., “Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia,” *Trends in Neurosciences*, vol. 31, no. 5, pp. 234–242, 2008.

[35] A. Meyer-Lindenberg, “From maps to mechanisms through neuroimaging of schizophrenia,” *Nature*, vol. 468, no. 7321, pp. 194–202, 2010.

[36] R. Field, A. G. Walker, and P. J. Conn, “Targeting glutamate synapses in schizophrenia,” *Trends in Molecular Medicine*, vol. 17, no. 12, pp. 689–698, 2011.
B. Moghaddam, "Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia," *Psychopharmacology*, vol. 174, no. 1, pp. 39–44, 2004.

B. Moghaddam and D. Javitt, "From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment," *Neuropsychopharmacology*, vol. 37, no. 1, pp. 4–15, 2012.

J. M. Stone, "Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?" *Therapeutic Advances in Psychopharmacology*, vol. 1, no. 1, pp. 5–18, 2011.

L. V. Kristiansen, I. Huerta, M. Beneyto, and J. H. Meadow-Woodruff, "NMDA receptors and schizophrenia," *Current Opinion in Pharmacology*, vol. 7, no. 1, pp. 48–55, 2007.

A. Marsman, M. P. van den Heuvel, D. W. J Klomp, R. S. Kahn, P. R. Luijten, and H. E. Hulshof Pol, "Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies," *Schizophrenia Bulletin*. In press.

J. M. Stone, P. D. Morrison, and L. S. Pilowsky, "Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review," *Journal of Psychopharmacology*, vol. 21, no. 4, pp. 440–452, 2007.

S. Nakanishi, "Molecular diversity of glutamate receptors and implications for brain function," *Science*, vol. 258, no. 5082, pp. 597–603, 1992.

J. N. C. Kew and J. A. Kemp, "Ionotropic and metabotropic glutamate receptor structure and pharmacology," *Psychopharmacology*, vol. 179, no. 1, pp. 4–29, 2005.

C. Konradi and S. Heckers, "Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment," *Pharmacology and Therapeutics*, vol. 97, no. 2, pp. 153–179, 2003.

B. Moghaddam, "Bringing order to the glutamate chaos in schizophrenia," *Neuron*, vol. 40, no. 5, pp. 881–884, 2003.

J. W. Olney, J. W. Newcomer, and N. B. Farber, "NMDA receptor hypofunction model of schizophrenia," *Journal of Psychiatric Research*, vol. 33, no. 6, pp. 523–533, 1999.

D. C. Javitt and S. R. Zukin, "Recent advances in the phenylcyclidine model of schizophrenia," *American Journal of Psychiatry*, vol. 148, no. 10, pp. 1301–1308, 1991.

J. W. Olney and N. B. Farber, "Glutamate receptor dysfunction and schizophrenia," *Archives of General Psychiatry*, vol. 52, no. 12, pp. 998–1007, 1995.

J. M. Stone, K. Erlandsson, E. Arstadt et al., "Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [11C]CNS-1261 SPET study," *Psychopharmacology*, vol. 197, no. 3, pp. 401–408, 2008.

J. H. Krystal, E. B. Perry, R. Guercioiuva et al., "Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function," *Archives of General Psychiatry*, vol. 62, no. 9, pp. 985–995, 2005.

H. Homayoun and B. Moghaddam, "NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons," *Journal of Neuroscience*, vol. 27, no. 43, pp. 11496–11500, 2007.

J. H. Krystal and B. Moghaddam, "Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia," in *Schizophrenia*, pp. 433–461, Wiley-Blackwell, 2011.

B. Moghaddam and A. L. Pehrson, "Disinhibition of prefrontal cortex neurons in schizophrenia," in *Advances in Schizophrenia*, W. F. Gattaz and G. Busatto, Eds., pp. 99–111, Springer, New York, NY, USA, 2010.

B. Moghaddam, B. Adams, A. Verma, and D. Daly, "Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex," *Journal of Neuroscience*, vol. 17, no. 8, pp. 2921–2927, 1997.

D. S. Lorrain, C. S. Baccei, L. J. Bristow, J. J. Anderson, and M. A. Varney, "Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268," *Neuroscience*, vol. 117, no. 3, pp. 697–706, 2003.

J. C. Neill, S. Barnes, S. Cook et al., "Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism," *Pharmacology and Therapeutics*, vol. 128, no. 3, pp. 419–432, 2010.

L. G. Coleman, L. F. Jarskog, S. S. Moy, and F. T. Crews, "Deficits in adult prefrontal cortex neurons and behavior following early post-natal NMDA antagonist treatment," *Pharmacology Biochemistry and Behavior*, vol. 93, no. 3, pp. 322–330, 2009.

N. Vasic, B. J. Connenmann, R. C. Wolf, H. Tumani, and J. Brettschneider, "Cerebrospinalfluid biomarker candidates of schizophrenia: where do we stand?" *European Archives of Psychiatry and Clinical Neuroscience*. In press.

L. S. Pilowsky, R. A. Bressan, J. M. Stone et al., "First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients," *Molecular Psychiatry*, vol. 11, no. 2, pp. 118–119, 2006.

L. S. Kegeles, X. Mao, A. D. Stanford et al., "Elevated prefrontal cortex y-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy," *Archives of General Psychiatry*, vol. 69, no. 5, pp. 449–459, 2012.

J. Théberge, R. Bartha, D. J. Drost et al., "Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers," *American Journal of Psychiatry*, vol. 159, no. 11, pp. 1944–1946, 2002.

J. Théberge, Y. Al-Semaan, P. C. Williamson et al., "Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS," *American Journal of Psychiatry*, vol. 160, no. 12, pp. 2231–2233, 2003.

K. Hashimoto, T. Fukushima, E. Shimizu et al., "Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia," *Archives of General Psychiatry*, vol. 60, no. 6, pp. 572–576, 2003.

V. Labrie, A. H. C. Wong, and J. C. Roder, "Contributions of the d-serine pathway to schizophrenia," *Neuropsychopharmacology*, vol. 62, no. 3, pp. 1484–1503, 2011.

J. F. Mothet, A. T. Parent, H. Wolosker et al., "D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 9, pp. 4926–4931, 2000.

N. C. Allen, S. Bagade, M. B. McQueen et al., "Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database," *Nature Genetics*, vol. 40, no. 7, pp. 831–834, 2008.

M. F. Egan, R. E. Straub, T. E. Goldberg et al., "Variation in GRM5 affects cognition, prefrontal glutamate, and risk..."
for schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 34, pp. 12604–12609, 2004.

[69] P. J. Harrison and D. R. Weinberger, “Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence,” Molecular Psychiatry, vol. 10, no. 1, pp. 40–68, 2005.

[70] T. L. Schwartz, S. Sachdeva, and S. M. Stahl, “Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia,” Current Pharmaceutical Design, vol. 18, no. 12, pp. 1580–1592, 2012.

[71] D. C. Javitt, “Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and Dopamine-GLutamate interactions,” in International Review of Neurobiology, A. D. Anissa and G. Olivier, Eds., pp. 69–108, Academic Press, 2007.

[72] P. Seeman, “Glutamate and dopamine components in schizophrenia,” Journal of Psychiatry and Neuroscience, vol. 34, no. 2, pp. 143–149, 2009.

[73] M. Laruelle, L. S. Kegeles, and A. Abi-Dargham, “Glutamate, dopamine, and schizophrenia from pathophysiology to treatment,” Annals of the New York Academy of Sciences, vol. 1003, pp. 138–158, 2003.

[74] M. Toda and A. Abi-Dargham, “Dopamine hypothesis of schizophrenia: making sense of it all,” Current Psychiatry Reports, vol. 9, no. 4, pp. 329–336, 2007.

[75] J. T. Coyle, “Glutamate and schizophrenia: beyond the dopamine hypothesis,” Cellular and Molecular Neurobiology, vol. 26, no. 4-6, pp. 365–384, 2006.

[76] J. M. Stone, O. D. Howes, A. Egerton et al., “Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis,” Biological Psychiatry, vol. 68, no. 7, pp. 599–602, 2010.

[77] K. L. Goa, S. R. Ross, and P. Chrisp, “Lamotrigine—a review of its pharmacological properties and clinical efficacy in epilepsy,” Drugs, vol. 46, no. 1, pp. 152–176, 1993.

[78] T. S. Premkumar and J. Pick, “Lamotrigine for schizophrenia,” Cochrane Database of Systematic Reviews, no. 4, article CD005962, 2006.

[79] J. Tiitinen, K. Wahlbeck, and V. Kiviniemi, “The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic meta-analysis and meta-analysis,” Schizophrenia Research, vol. 70, no. 1–3, pp. 10–14, 2009.

[80] H. D. Langtry, J. C. Gillis, and R. Davis, “Topiramate: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy,” Drugs, vol. 54, no. 5, pp. 752–773, 1997.

[81] H. Alshar, H. Roohafza, G. Mousavi et al., “Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial,” Journal of Psychopharmacology, vol. 23, no. 2, pp. 157–162, 2009.

[82] M. K. Hahn, G. Remington, D. Bois, and T. Cohn, “Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects,” Journal of Clinical Psychopharmacology, vol. 30, no. 6, pp. 706–710, 2010.

[83] M. Muscatello, A. Bruno, G. Pandolfo et al., “Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study,” Journal of Psychopharmacology, vol. 25, no. 5, pp. 667–674, 2011.

[84] J. C. González, J. Egea, M. Del Carmen Godino et al., “Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca2+ signalling in hippocampal neurons,” European Journal of Neuroscience, vol. 26, no. 9, pp. 2481–2495, 2007.

[85] Y. Levkovitz, S. Mendlovich, S. Riwkes et al., “A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia,” Journal of Clinical Psychiatry, vol. 71, no. 2, pp. 138–149, 2010.

[86] T. Miyaoaka, R. Yasukawa, H. Yasuda, M. Hayashida, T. Inagaki, and J. Horiguchi, “Possible antipsychotic effects of minocycline in patients with schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 1, pp. 304–307, 2007.

[87] T. Miyaoaka, R. Yasukawa, H. Yasuda, M. Hayashida, T. Inagaki, and J. Horiguchi, “Minocycline as adjunctive therapy for schizophrenia: an open-label study,” Clinical Neuropharmacology, vol. 31, no. 5, pp. 287–292, 2008.

[88] B. A. Ellenbroek, “Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?” Neuropharmacology, vol. 62, no. 3, pp. 1371–1380, 2011.

[89] R. W. Buchanan, D. C. Javitt, S. R. Marder et al., “The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments,” American Journal of Psychiatry, vol. 164, no. 10, pp. 1593–1602, 2007.

[90] G. E. Tsai and P. Y. Lin, “Strategies to enhance N-Methyl-D-Aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis,” Current Pharmaceutical Design, vol. 16, no. 5, pp. 522–537, 2010.

[91] L. Schwieler, K. R. Linderholm, L. K. Nilsson-Todd, S. Erhardt, and G. Engberg, “Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area,” Life Sciences, vol. 83, no. 5-6, pp. 170–175, 2008.

[92] G. E. Tsai, P. Yang, L. C. Chung, I. C. Tsai, C. W. Tsai, and J. T. Coyle, “D-serine added to clozapine for the treatment of schizophrenia,” American Journal of Psychiatry, vol. 156, no. 11, pp. 1822–1825, 1999.

[93] J. T. Kantrowitz, A. K. Malhotra, B. Cornblatt et al., “High dose D-serine in the treatment of schizophrenia,” Schizophrenia Research, vol. 121, no. 1–3, pp. 125–130, 2010.

[94] D. V. Ferraris and T. Tsukamoto, “Recent advances in the therapeutic utility in schizophrenia, a critical review and meta-analysis,” Current Pharmaceutical Design, vol. 17, no. 2, pp. 103–111, 2011.

[95] S. M. Smith, J. M. Uslander, and P. H. Hutson, “The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors,” Open Medicinal Chemistry Journal, vol. 4, no. 1, pp. 3–9, 2010.

[96] H. Y. Lane, C. L. Huang, P. L. Wu et al., “Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to clozapine for the treatment of schizophrenia,” Biological Psychiatry, vol. 60, no. 6, pp. 645–649, 2006.

[97] H. Y. Lane, Y. C. Chang, Y. C. Liu, C. C. Chiu, and G. E. Tsai, “Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study,” Archives of General Psychiatry, vol. 62, no. 11, pp. 1196–1204, 2005.

[98] H. Y. Lane, C. H. Lin, Y. J. Huang, Y. C. Chang, and G. E. Tsai, “A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia,” International Journal of Neopsychopharmacology, vol. 13, no. 4, pp. 451–460, 2010.
[99] G. Tsai, H. Y. Lane, P. Yang, M. Y. Chong, and N. Lange, “Glycine transporter 1 inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia,” *Biological Psychiatry*, vol. 55, no. 5, pp. 452–456, 2004.

[100] H. Y. Lane, Y. C. Liu, C. L. Huang et al., “Sarcosine (N-Methylglycine) treatment for acute schizophrenia: a Randomized, Double-Blind study,” *Biological Psychiatry*, vol. 63, no. 1, pp. 9–12, 2008.

[101] D. Alberati, J.-L. Moreau, J. Lengyel et al., “Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia,” *Neuropharmacology*, vol. 62, no. 2, pp. 1152–1161, 2012.

[102] E. Pinard, A. Alanine, D. Alberati et al., “Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2, 2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia,” *Journal of Medicinal Chemistry*, vol. 53, no. 12, pp. 4603–4614, 2010.

[103] J. H. Krystal, W. Abi-Saab, E. Perry et al., “Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY535470, in healthy human subjects,” *Psychopharmacology*, vol. 179, no. 1, pp. 303–309, 2005.

[104] R. G. Greenslade and S. N. Mitchell, “Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell,” *Neuropharmacology*, vol. 47, no. 1, pp. 1–8, 2004.

[105] D. D. Schoepp and G. J. Marek, “Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?” *Curr Drug Target CNS Neurol Disord*, vol. 1, no. 2, pp. 215–225, 2002.

[106] M. J. Fell, D. L. McKinzie, J. A. Monn, and K. A. Svensson, “Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia,” *Neuropharmacology*, vol. 62, no. 3, pp. 1473–1483, 2011.

[107] S. T. Patil, L. Zhang, F. Martenyi et al., “Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial,” *Nature Medicine*, vol. 13, no. 9, pp. 1102–1107, 2007.

[108] P. N. Vinson and P. J. Conn, “Metabotropic glutamate receptors as therapeutic targets for schizophrenia,” *Neuropharmacology*, vol. 62, no. 3, pp. 1461–1472, 2011.

[109] P. J. Conn, C. W. Lindsley, and C. K. Jones, “Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia,” *Trends in Pharmacological Sciences*, vol. 30, no. 1, pp. 25–31, 2009.

[110] G. Riedel, B. Platt, and J. Micheau, “Glutamate receptor function in learning and memory,” *Behavioural Brain Research*, vol. 140, no. 1-2, pp. 1–47, 2003.

[111] R. K. Wong, R. Bianchi, S. C. Chuang, and L. R. Merlin, “Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGluR1 and mGluR5 and implications for antiepileptic drug design,” *Epilepsy Currents*, vol. 5, no. 2, pp. 63–68, 2005.

[112] P. Jeffrey Conn, A. Christopoulos, and C. W. Lindsley, “Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders,” *Nature Reviews Drug Discovery*, vol. 8, no. 1, pp. 41–54, 2009.

[113] K. Leach, P. M. Sexton, and A. Christopoulos, “Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology,” *Trends in Pharmacological Sciences*, vol. 28, no. 8, pp. 382–389, 2007.

[114] G. G. Kinney, J. A. O’Brien, W. Lemaire et al., “A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 313, no. 1, pp. 199–206, 2005.

[115] M. R. Stefani and B. Moghaddam, “Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade,” *European Journal of Pharmacology*, vol. 639, no. 1–3, pp. 26–32, 2010.

[116] F. Liu, S. Grauer, C. Kelley et al., “ADX47273 [S-(4-Fluoro-phenyl)–3-[3-(4-fluoro-phenyl)–1,2,4-oxadiazol-5-yl]–piperidin-1-yl]–methanone: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 327, no. 3, pp. 827–839, 2008.

[117] C. Schlumberger, M. Pietraszek, A. Gravuis, and W. Danysz, “Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia,” *Pharmacology Biochemistry and Behavior*, vol. 95, no. 1, pp. 23–30, 2010.

[118] M. J. Fell, K. A. Svensson, B. G. Johnson, and D. D. Schoepp, “Evidence for the role of metabotropic glutamate (mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (−)-(1R,5S,5S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039),” *Journal of Pharmacology and Experimental Therapeutics*, vol. 326, no. 1, pp. 209–217, 2008.

[119] R. Galici, N. G. Echemendia, A. L. Rodriguez, and P. J. Conn, “A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 315, no. 3, pp. 1181–1187, 2005.

[120] R. Galici, C. K. Jones, K. Hemstapat et al., “Biphenylindanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 318, no. 1, pp. 173–185, 2006.

[121] E. A. Hackler, N. E. Byun, C. K. Jones et al., “Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation,” *Neuroscience*, vol. 168, no. 1, pp. 209–218, 2010.

[122] A. B. Pinkerton, R. V. Cube, J. H. Hutchinson et al., “Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2) Part 1: identification and synthesis of phenyltetrazolyl acetophenones,” *Bioorganic and Medicinal Chemistry Letters*, vol. 14, no. 21, pp. 5329–5332, 2004.

[123] J. A. Gray and B. L. Roth, “Molecular targets for treating cognitive dysfunction in schizophrenia,” *Schizophrenia Bulletin*, vol. 33, no. 5, pp. 1100–1119, 2007.

[124] L. J. Porroni, J. B. Daunais, G. A. Rogers, R. E. Hampson, and S. A. Deadwyler, “Facilitation of task performance and memory by pretreatment with the group II metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 318, no. 1, pp. 173–185, 2010.

[125] D. C. Goff, L. Leahy, I. Berman et al., “A placebo-controlled pilot study of the ampakine CX516 added to clozapine in
schizophrenia,” *Journal of Clinical Psychopharmacology*, vol. 21, no. 5, pp. 484–487, 2001.

[126] D. C. Goff, J. S. Lamberti, A. C. Leon et al., “A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia,” *Neuropsychopharmacology*, vol. 33, no. 3, pp. 465–472, 2008.

[127] G. T. Swanson, “Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?” *Neuropsychopharmacology*, vol. 34, no. 1, pp. 249–250, 2009.

[128] J. E. C. Hallak, S. M. Dursun, D. C. Bosi et al., “The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 35, no. 1, pp. 198–202, 2011.

[129] P. Roser, F. X. Vollenweider, and W. Kawohl, “Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists,” *World Journal of Biological Psychiatry*, vol. 11, no. 2, pp. 208–219, 2010.

[130] A. W. Zuardi, J. A. S. Crippa, J. E. C. Hallak, F. A. Moreira, and F. S. Guimarães, “Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug,” *Brazilian Journal of Medical and Biological Research*, vol. 39, no. 4, pp. 421–429, 2006.

[131] A. Shekhar, W. Z. Potter, J. Lightfoot et al., “Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia,” *American Journal of Psychiatry*, vol. 165, no. 8, pp. 1033–1039, 2008.

[132] J. Wess, R. M. Eglen, and D. Gautam, “Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development,” *Nature Reviews Drug Discovery*, vol. 6, no. 9, pp. 721–733, 2007.